IDEAYA BIOSCIENCES INC (IDYA) Stock Price, Quote, News and Overview
NASDAQ:IDYA - Nasdaq - US45166A1025 - Common Stock - Currency: USD
IDYA Quote, Performance and Key Statistics
21.85
+0.12 (+0.55%)
The current stock price of IDYA is 21.85 USD. In the past month the price decreased by -6.18%. In the past year, price decreased by -52.38%.
IDYA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IDYA
Company Profile
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 124 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Company Info
IDEAYA BIOSCIENCES INC
7000 Shoreline Ct, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Yujiro Hata
Employees: 124
Company Website: https://www.ideayabio.com/
Investor Relations: https://ir.ideayabio.com/
Phone: 16504436209
IDEAYA BIOSCIENCES INC / IDYA FAQ
What is the stock price of IDEAYA BIOSCIENCES INC today?
The current stock price of IDYA is 21.85 USD. The price increased by 0.55% in the last trading session.
What is the ticker symbol for IDEAYA BIOSCIENCES INC stock?
The exchange symbol of IDEAYA BIOSCIENCES INC is IDYA and it is listed on the Nasdaq exchange.
On which exchange is IDYA stock listed?
IDYA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IDEAYA BIOSCIENCES INC stock?
20 analysts have analysed IDYA and the average price target is 52.88 USD. This implies a price increase of 142.03% is expected in the next year compared to the current price of 21.85. Check the IDEAYA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IDEAYA BIOSCIENCES INC worth?
IDEAYA BIOSCIENCES INC (IDYA) has a market capitalization of 1.89B USD. This makes IDYA a Small Cap stock.
How many employees does IDEAYA BIOSCIENCES INC have?
IDEAYA BIOSCIENCES INC (IDYA) currently has 124 employees.
What are the support and resistance levels for IDEAYA BIOSCIENCES INC (IDYA) stock?
IDEAYA BIOSCIENCES INC (IDYA) has a support level at 21 and a resistance level at 23.57. Check the full technical report for a detailed analysis of IDYA support and resistance levels.
Is IDEAYA BIOSCIENCES INC (IDYA) expected to grow?
The Revenue of IDEAYA BIOSCIENCES INC (IDYA) is expected to grow by 226.3% in the next year. Check the estimates tab for more information on the IDYA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IDEAYA BIOSCIENCES INC (IDYA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IDYA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IDYA, evaluating the profitability, health, valuation and growth aspects
- IDEAYA BIOSCIENCES INC (IDYA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IDEAYA BIOSCIENCES INC (IDYA) Sales and EPS estimates to see what analysts future expectations are.
- IDEAYA BIOSCIENCES INC (IDYA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IDEAYA BIOSCIENCES INC (IDYA) Insider and Institutional Ownership to learn about the owners and their transactions.
- IDEAYA BIOSCIENCES INC (IDYA) Stock Chart to make your own analysis
- IDEAYA BIOSCIENCES INC (IDYA) Latest news and press-releases to stay up to date.
Does IDEAYA BIOSCIENCES INC (IDYA) stock pay dividends?
IDYA does not pay a dividend.
When does IDEAYA BIOSCIENCES INC (IDYA) report earnings?
IDEAYA BIOSCIENCES INC (IDYA) will report earnings on 2025-05-05.
What is the Price/Earnings (PE) ratio of IDEAYA BIOSCIENCES INC (IDYA)?
IDEAYA BIOSCIENCES INC (IDYA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.3).
What is the Short Interest ratio of IDEAYA BIOSCIENCES INC (IDYA) stock?
The outstanding short interest for IDEAYA BIOSCIENCES INC (IDYA) is 11.2% of its float. Check the ownership tab for more information on the IDYA short interest.
IDYA Technical Analysis
IDYA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IDYA. IDYA has a great financial health rating, but its profitability evaluates not so good.
IDYA Financial Highlights
Over the last trailing twelve months IDYA reported a non-GAAP Earnings per Share(EPS) of -3.3. The EPS decreased by -67.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.37% | ||
| ROE | -15.09% | ||
| Debt/Equity | 0 |
IDYA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to IDYA. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 11.16% and a revenue growth 226.3% for IDYA